AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

Summary

This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension

Timeline

Start

2020-11-16

Primary completion

2029-04

Completion

2029-04

Drugs

Indications